US 2025/0375535 A1 · FUSION TYPE ADENO-ASSOCIATED VIRUS AND USE THEREOF

Abstract

The present invention relates to the field of biological medicines. Disclosed are a fusion adeno-associated virus and a use thereof in otological disease and ophthalmic diseases. The fusion adeno-associated virus comprises a fusion peptide fragment formed by fusion of peptide fragments of serotypes AAV1, AAV2, AAV6 and AAV7, or a variant thereof, and can efficiently infect an RPE layer for the treatment of ophthalmic diseases. The fusion adeno-associated virus has a wide application prospect in the treatment of ophthalmic diseases as a safe vector.

Claims21

Dependent claims

A fusion adeno-associated virus capsid protein, characterized in that the capsid protein comprises a fusion peptide fragment of peptide fragments from serotypes AAV1, AAV2, AAV6 and AAV7, or a variant thereof.

Dependencies are inferred from the claim text.

Facts

Application

18/856,580Filed 11 Apr 2023

Priority

CN 202210383577.X12 Apr 2022

Published

11 Dec 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 48/0058
Characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered: nucleic acids adapted for tissue…
A61P 27/02
Drugs for disorders of the senses: ophthalmic agents
A61K 35/761
Viruses; Subviral particles; Bacteriophages: adenovirus
A61K 48/005
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy:…

Fusion type adeno-associated virus and use thereof

Life of this patent

Fusion type adeno-associated virus and use thereof

Life of this patent

Abstract

Claims21